Literature DB >> 12833134

Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect.

Ja Young Seol1, Kyung-Ho Park, Chang-Il Hwang, Woong-Yang Park, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Choon-Taek Lee.   

Abstract

TRAIL is a cytokine with a unique ability to induce apoptosis selectively in many transformed cell lines. The instability of TRAIL and the resistance of some cancer cells to TRAIL present the main obstacles for clinical experimentation. We generated an adenovirus expressing full-length TRAIL and tested its efficacy in several cancer cell lines. Ad-TRAIL-infected cancer cells localized full-length TRAIL protein to the cytoplasm and released same-sized TRAIL in the media. Ad-TRAIL was found to induce apoptotic cell death in several cancer cell lines resistant to soluble TRAIL (A549, SKOV3, HT-29 and LNCap) and in TRAIL-sensitive cell lines. Ad-TRAIL, but not soluble TRAIL, induced apoptotic cell death in TRAIL-resistant cell lines, manifested by an increased sub-G1 proportion, caspase-3 activation and PARP cleavage. Ad-TRAIL also induced a media-transferable bystander effect, but only in soluble TRAIL-sensitive cell lines. In conclusion, two novel characteristics of ad-TRAIL were found during this study. First, that ad-TRAIL can induce apoptotic cell death in several cancer cell lines resistant to sTRAIL. Second, that ad-TRAIL induces a media-transferable bystander effect, which is expected to increase its therapeutic value by allowing TRAIL to overcome the locally acting nature and low transduction rate commonly encountered in clinical situation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833134     DOI: 10.1038/sj.cgt.7700597

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  23 in total

1.  Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

Authors:  J Woraratanadharm; S Rubinchik; H Yu; F Fan; S M Morrow; J Y Dong
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

2.  Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells.

Authors:  Yanbo Li; Caixia Guo; Zhicheng Wang; Pingsheng Gong; Zhiwei Sun; Shouliang Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

3.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

4.  Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids.

Authors:  Cédric Chaveroux; Alain Bruhat; Valérie Carraro; Céline Jousse; Julien Averous; Anne-Catherine Maurin; Laurent Parry; Florent Mesclon; Yuki Muranishi; Pierre Cordelier; Aline Meulle; Patrick Baril; Anh Do Thi; Philippe Ravassard; Jacques Mallet; Pierre Fafournoux
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

Review 5.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 6.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

7.  In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus.

Authors:  Fang Li; Yi Guo; Lingfei Han; Yankang Duan; Fang Fang; Sumei Niu; Qiujie Ba; Huaishi Zhu; Fanfei Kong; Chao Lin; Xuejun Wen
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

8.  The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Anfernee Kai-Wing Tse; Ka-Yu Chow; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Guo-Yuan Zhu; Yiu-Cheong Wu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

9.  Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA.

Authors:  Jianjun Zhang; Shenglin Huang; He Zhang; Haibo Wang; Haiyan Guo; Guanxiang Qian; Xianqun Fan; Jian Lu; Andrew R Hoffman; Ji-Fan Hu; Shengfang Ge
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

10.  Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.

Authors:  Norman Kock; Randa Kasmieh; Ralph Weissleder; Khalid Shah
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.